Did you know?

The IWMF raised more than five million dollars for WM medical research

Did you know?

The IWMF raised more than 60 support groups in North America and nearly 20 others world-wide

Did you know?

The IWMF has a current worldwide membership of nearly 4,000

Did you know?

IWMF-TALK is a wonderful place to share information and learn from other survivors

Did you know?

Each year 1,500 new cases of Waldenstrom's macroglobulinemia are diagnosed in the USA

Did you know?

Volunteers at the IWMF Telephone Lifeline are waiting to share their experiences with you

Did you know?

You can order DVD recordings of past WM Educational Forums online or by mail

Did you know?

All IWMF programs and services are funded by WM survivors, caregivers, friends, and family

Current Grant Recipients

TARGETING THE TUMOR MICROENVIRONMENT IN WALDENSTROM'S MACROGLOBULINEMIA

 

Project Period: 11/15/2013 - 11/15/2015                     Investigator: Sherine Elsawa, PhD

                                                                                              Institution: Northern Illinois University, Dekalb, IL (USA)

 

A study to determine the translational significance of targeting the CCR3-P13K-AKT-GL12 pathway - a novel signaling pathway regulating the crosstalk between malignant compartments and the tumor microenvironment; and increase the understanding of the signaling pathways in the tumor microenvironment that contribute to the progression of WM, with the purpose of facilitating the development of new targeted therapies for WM patients.

 


 

DEVELOPMENT OF TARGETED THERAPIES FOR WALDENSTROM’S MACROGLOBULINEMIA



Project Period 6/1/2013 - 5/31/2015                           Investigator:  Steven P. Treon, MD, PhD
                                                                                               Institution:   Dana-Farber Cancer Institute, Boston, MA (USA)

This is a continuation of a previous project proposed by Dr. Treon and partially funded by the IWMF.  This current study proposes to define the oncogenic signaling of MYD88 L265P in WM, to identify and validate inhibitors of MYD88-directed signaling in WM, and to characterize MYD88 pathway inhibitors in vivo and initiate early clinical phase studies in WM patients.

 


 

DEVELOPMENT OF A MOUSE GENETIC MODEL OF WALDENSTROM’S MACROGLOBULINEMIA



Project Period:  12/1/2012 - 11/30/2015                       Investigator:  Ruben Carrasco, MD, PhD
                                                                                               Institution:   Dana-Farber Cancer Institute, Boston, MA (USA)

A study jointly funded by the Leukemia & Lymphoma Society and Waldenstrom’s Macroglobulinemia Foundation of Canada (an IWMF affiliate) to generate a mouse model of the disease that recapitulates its clinicopathologic features by engineering the MYD88 L265P mutation in the mice. These mice will be evaluated for LPL/WM involvement over time as well as biochemical and functional characterization of transgenic B-cells to define the role of MYD88 L265P mutation in oncogenesis
 

 


 

THE ROLE OF HYPOXIA IN THE DISSEMINATION OF WALDENSTROM MACROGLOBULINEMIA



Project Period:  7/1/2012 - 8/01/2014                           Investigator:  Abdel Kareem Azab, PhD
                                                                                               Institution:   Washington University, St. Louis, MO (USA)

A study to determine the role of hypoxia in WM cell dissemination in vivo, to characterize molecular changes regulated by hypoxia in WM cells in vitro, and to determine the role of a signaling pathway called Hypoxia Inducible Factor (HIF) in WM cell response to hypoxia and the effect of HIF inhibitors on the progression of WM in vitro and in vivo.

 

 


 

THE FACTORS REGULATING IMMUNOGLOBULIN-PRODUCING B-CELLS IN PATIENTS WITH WALDENSTROM’S MACROGLOBULINEMIA



Project Period:
  11/1/2011 - 10/31/2014                        Investigator:  Stephen M. Ansell, MD, PhD
                                                                                                Institution:   Mayo Clinic, Rochester, MD (USA)
   
A continuation of previous projects proposed by Dr. Ansell and funded by the IWMF. This current study proposes to characterize the expression and activation of STAT5A and STAT5B in WM cell lines and patient-derived tumor cells, to determine the individual influence of STAT5A and STAT5B on the subsequent expression of downstream targets in WM, and to evaluate the effects of isoform-specific STAT5 inhibition on the biology of the WM tumor.

 

 


 

LARGE SCALE GENOMIC AND PROTEOMIC PROFILING IN WALDENSTROM’S MACROGLOBULINEMIA



Project Period:  9/1/2010 - 11/1/2016                            Investigator:  Irene Ghobrial, MD
                                                                                               Institution:   Dana Farber Cancer Institute, Boston, MA (USA)

A study to develop a tissue bank of WM specimens linked to clinical characteristics of patients in different stages of the disease, to characterize the genetics and proteomics of WM cells during disease progression, and to develop biomarkers that evaluate in vivo activity of therapeutic agents in WM patients treated in clinical trials.

 


To participate in IWMF's Tissue Bank Project, click here.